Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0952W HIGH $5.47
Volume
166.47 K
Value Traded
709.45 K
Short % Float
4.2%
-6.46%Week
-12.13%1 Month
+3.96%3 Month
+18.98%6 Month
-63.73%5 Year
+2,643.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
174.71 M
EPS (TTM)
4.20
P/E Ratio
1.00
Ent. Value
136.75 M
Total Shares
41.59 M
Float Shares
31.11 M
Insiders
25.21%
Institutions
40.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ORMP Catalyst Timeline
Dated clinical, regulatory and corporate events for Oramed Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oramed Pharmaceuticals Inc.
554Total events
0Upcoming
106Tier-1 (high impact)
2008 to 2026Coverage
Event history 50
▲Milestone PaymentCorporate
Received $18 million payment from Scilex Holdings, closing out Option Agreement obligations
▲Equity OfferingCorporate
Additional open market purchases of Alpha Tau shares through Sep 30, 2025
▲Partnership / LicenseCorporate
Oramed closes $36.9M strategic investment in Alpha Tau and enters three-year service agreement
▲Equity OfferingCorporate
Investment in Alpha Tau Medical: $36.9M initial purchase on April 24, 2025
●NDA SubmissionRegulatory Filing
HTIT submitted Marketing Authorization Application to China's regulators for oral insulin capsule
diabetessource ↗
▲Partnership / LicenseCorporate
Oramed enters into definitive agreements to spin off POD technology into joint venture OraTech with HTIT
▼Equity OfferingCorporate
Oramed plans to distribute OraTech stock to shareholders via dividend
▲Milestone PaymentCorporate
Next $20 million installment from Scilex Senior Secured Note expected
▲Equity OfferingCorporate
Board authorizes up to $20M common stock repurchase plan over 12 months
▲Milestone PaymentCorporate
Oramed receives $40 million out of $102 million principal from Scilex Senior Secured Note
▲Trial CompletionTrial
HTIT successfully completed Phase 3 trial of oral insulin in China
type 2 diabetessource ↗
◆Trial InitiationTrial
Intend to initiate a new Phase 3 oral insulin trial in the U.S. under a differentiated protocol
type 2 diabetessource ↗
▲Partnership / LicenseCorporate
Entered into definitive agreement with HTIT for a joint venture centered on oral drug delivery technology
◆Other Regulator MilestoneEx-US Regulatory
HTIT in final stages of regulatory approval for oral insulin in China
type 2 diabetessource ↗
◆FDA ApprovalORMD-0801FiledFDA Decision
Potential FDA approval for ORMD-0801 by Q1 2024
Type 2 Diabetessource ↗
▲Partnership / LicenseCorporate
Entered into exclusive Licensing Agreement with an international consumer product and pharmaceutical group for PeriTech pipeline
●Equity OfferingCorporate
Scilex issued Senior Secured Promissory Note to Oramed with warrants
▲Partnership / LicenseCorporate
Oramed signs non-binding term sheet with HTIT to form joint venture for oral drug delivery technology
◆Oral PresentationPresentation
Oral presentation at ADA 83rd Scientific Sessions on Phase 2 oral insulin trial for NASH
NASH and Type 2 Diabetessource ↗
◆Oral PresentationPresentation
Presentation at Novel Therapies for Type 2 Diabetes & Obesity Summit
Type 2 Diabetes & Obesitysource ↗
▲Full ResultsClinical Data
Oramed completes analysis of US Phase 3 oral insulin trial (ORA-D-013-1)
type 2 diabetessource ↗
◆Additional DataORMD-0801FiledClinical Data
Comprehensive analysis of unblinded Phase 3 data
diabetessource ↗
▼Topline ReadoutORMD-0801FiledClinical Data
Top-line results from Phase 3 trial of ORMD-0801 for Type 2 Diabetes
Type 2 Diabetessource ↗
▼Primary Endpoint MissedORMD-0801FiledClinical Data
Primary endpoint not met in Phase 3 trial of ORMD-0801
Type 2 Diabetessource ↗
▼Program DiscontinuationORMD-0801FiledCorporate
Oramed expects to discontinue oral insulin clinical activities for T2D
Type 2 Diabetessource ↗
▲Patent GrantedIP / Competition
U.S. patent granted for oral GLP-1 & insulin combination therapy for diabetes
diabetessource ↗
▼Primary Endpoint MissedClinical Data
U.S. Phase 3 oral insulin trial did not meet primary or secondary endpoints
type 2 diabetessource ↗
▼Trial DiscontinuedTrial
U.S. Phase 3 oral insulin trial did not meet primary or secondary endpoints
type 2 diabetessource ↗
◆Topline ReadoutORMD-0801FiledClinical Data
Top-line data from Phase 3 trial of oral insulin for T2D expected
Type 2 Diabetessource ↗
◆Enrollment UpdateORMD-0801FiledTrial
ORA-D-013-2 enrollment ongoing, expected completion in 2023
type 2 diabetessource ↗
◆Quarterly UpdateORMD-0901Corporate
Update on ORMD-0901 oral GLP-1 trial progress expected in coming weeks
diabetessource ↗
▲PublicationORMD-0801FiledPresentation
Publication of oral insulin (ORMD-0801) dose-finding study in Diabetes, Obesity, and Metabolism
Type 2 Diabetessource ↗
▲Full ResultsORMD-0801FiledClinical Data
Additional positive safety and efficacy data from Phase 2 trial of ORMD-0801 for NASH
NASHsource ↗
◆Oral PresentationORMD-0801FiledPresentation
Webinar highlighting safety and efficacy data from Phase 2 trial of ORMD-0801 for NASH
non-alcoholic steatohepatitis (NASH)source ↗
Past FDA Catalysts and PDUFA Decisions
How ORMP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | ORMD-0801 | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C58 / 100
Pipeline Score
$1.4B
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
7.6x
rNPV / MCap
Top 9%
Micro Cap(rank 60 of 658)
Percentile Rank
Oramed Pharmaceuticals Inc. carries a moderate pipeline score (58/100), with $11.3B risk-adjusted pipeline value, led by ORMD-0801 in Type 2 Diabetes Mellitus (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMD-0801 Small moleculeNCT04564846 | Type 2 Diabetes Mellitus | Phase 3 | COMPLETED | 380 | Jun 7, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ORMP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ORMD-0801 | Type 2 Diabetes | Phase 3 | 2023-01-11 | 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agentsRead More | Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hexter JoshuaOfficer (COO & CBO) | Sell | -30,000 1,328,130 held | $4.51 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ORMP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ORMP for Q2 2026. | ||||
ORMP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ORMP ranks across every disease it competes in
Competitive Position is a premium feature
See how ORMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialORMP News
ORMP▲ +5.3%on this news
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals has announced its inclusion in the Russell 2000 and 3000 indexes, which is expected to enhance its visibility and trading liquidity. The company has significantly repaid its Scilex loan, recovering approximately $118 million of the $99.5 million loan. Additionally, Oramed's total cash and assets have reached around $270 million, reflecting a strengthened balance sheet. The letter from CEO Nadav Kidron outlines the company's strategic investments and operational progress.
Read more →ORMPOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Oramed Pharmaceuticals Inc. has announced its upcoming inclusion in the Russell 2000 and Russell 3000 indexes, effective June 29, 2026. This membership is based on market capitalization rankings and will enhance the company's visibility among investors. The Russell indexes are significant benchmarks for investment strategies, with trillions of dollars in assets tied to them.
Read more →ORMPOramed and Lifeward Announce Strategic Transaction
Oramed Pharmaceuticals has entered into a strategic transaction with Lifeward, transferring its Protein Oral Drug (POD™) delivery technology while acquiring a 49.9% ownership stake in Lifeward. The deal includes a $10 million investment in senior secured convertible notes. This partnership aims to enhance Oramed's exposure to oral drug delivery innovation and Lifeward's growth in medical robotics.
Read more →ORMP▲ +6.5%on this news
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Oramed Pharmaceuticals has received an $18 million payment from Scilex Holdings, fulfilling its obligations under an Option Agreement. This payment increases Oramed's total returns from its Scilex investment to $118 million. Additionally, the Board has approved a cash dividend of $0.25 per share, set to be distributed on January 26, 2026, rewarding shareholders with an aggregate of approximately $10.5 million.
Read more →ORMPOramed Reports Fiscal Third Quarter 2025 Financial Results
Oramed Pharmaceuticals reported strong financial results for the nine months ending September 30, 2025, with total assets increasing by 42% to $220.5 million. The company's net income reached $65 million, largely due to cash returns from Scilex Holding Company and gains from investments in Alpha Tau Medical Ltd. CEO Nadav Kidron highlighted the effectiveness of their investment strategy in enhancing financial flexibility for future opportunities.
Read more →ORMPORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
Oramed Pharmaceuticals Inc. has announced a dividend distribution of common stock purchase rights to enhance shareholder protection against hostile takeovers. Each shareholder will receive one right per share, allowing them to purchase additional shares at a set price if certain ownership thresholds are met. The rights will expire in three years unless redeemed or exchanged earlier.
Read more →ORMPOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Pharmaceuticals has released a letter to shareholders detailing advancements in its oral insulin program and strategic investments. The company plans to initiate a 60-patient trial in the US to validate its oral insulin formulation. Despite terminating a joint venture, Oramed continues to pursue independent development and has seen significant investment returns.
Read more →ORMPOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals has announced a strategic investment of $36.9 million in Alpha Tau Medical, acquiring approximately 14.1 million shares. This partnership aims to leverage Oramed's capital markets expertise to support Alpha Tau's innovative cancer therapy, Alpha DaRT. The collaboration includes a three-year service agreement and the appointment of two directors from Oramed to Alpha Tau's board.
Read more →ORMP▲ +7%on this news· ran to +28% by day 3
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals has issued a letter to shareholders detailing its achievements and future plans. The company is advancing its oral drug delivery technology through a joint venture with Hefei Tianhui Biotech, which is expected to support a Phase 3 clinical trial for oral insulin. Oramed also plans to distribute OraTech stock to shareholders and is evaluating cash dividends to enhance shareholder value.
Read more →ORMP▲ +19.8%on this news
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals has announced a joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. to enhance the development of its oral insulin product, ORMD-0801. This venture aims to leverage advanced manufacturing capabilities and significant financial investment to accelerate commercialization. Oramed shareholders will benefit from a majority equity interest in OraTech, which is set to reinitiate a pivotal Phase 3 clinical trial in the U.S.
Read more →ORMPOramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals has announced a restructuring of its debt with Scilex Holding Company, involving the execution of agreements for new convertible notes worth $50 million. This restructuring includes a repayment of $22.5 million of existing debt and an anticipated royalty on Scilex's product sales. Oramed's CEO expressed optimism about the potential value of this investment.
Read more →ORMPOramed Letter to Shareholders
Oramed Pharmaceuticals has issued a letter to shareholders outlining recent developments, including a $20 million stock repurchase program and a new Phase 3 oral insulin trial protocol. The company is also finalizing a joint venture with Hefei Tianhui Biotech Co., Ltd. to enhance its oral drug delivery technology. Oramed's CEO emphasizes the company's strong cash position and commitment to advancing its initiatives.
Read more →ORMPOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Oramed Pharmaceuticals Inc. has announced a stock buy-back program authorized by its Board of Directors, allowing for the repurchase of up to $20 million in common stock over the next 12 months. The company will have discretion over the timing and number of shares purchased, depending on market conditions and other factors. This initiative aims to enhance shareholder value, although it does not obligate the company to buy back shares.
Read more →ORMPOramed’s Letter to Shareholders
Oramed Pharmaceuticals has announced a new Phase 3 oral insulin trial in the U.S. following a review of previous trial data that identified responsive patient subpopulations. The company is also forming a joint venture with HTIT, which has completed its own Phase 3 trials in China. Additionally, Oramed has acquired technology from PeriTech to enhance its product offerings.
Read more →ORMPOramed Letter to Shareholders Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing
Oramed Pharmaceuticals has provided an update indicating plans to initiate a Phase 3 oral insulin trial in the U.S. under a new protocol, following an analysis showing promising results in specific patient subpopulations. Their partner, HTIT, has successfully completed a Phase 3 trial in China for oral insulin and is investing substantially in commercial production. Additionally, Oramed has formed a joint venture with HTIT to further develop and market their oral insulin technology. Despite facing setbacks with previous trial results, the company's strategy now focuses on leveraging new data and partnerships to enhance shareholder value.
Read more →ORMPOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
Oramed Pharmaceuticals has entered into a $101.875 million Senior Secured Note agreement with Scilex Holding Company. This transaction replaces a previous agreement with Sorrento Therapeutics and includes warrants for purchasing Scilex stock. The deal aims to support Scilex's growth while providing Oramed with financial leverage. However, there are risks related to Scilex's debt obligations and stock market fluctuations.
Read more →ORMPOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company 18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scil
Oramed Pharmaceuticals Inc. has entered into a Securities Purchase Agreement with Scilex Holding Company, resulting in a $101.87 million Senior Secured Promissory Note transaction. This deal allows Scilex to assume a substantial term loan from Sorrento Therapeutics, facilitating a purchase of Scilex's equity interests. As part of the agreement, Oramed received warrants for up to 17 million shares of Scilex, although there are noted risks concerning Scilex's ability to manage the new debt and maintain liquidity.
Read more →ORMPExecution Version NON-BINDING
Oramed Pharmaceuticals has issued a non-binding term sheet outlining proposed transactions involving Scilex Holding Company and Sorrento Therapeutics. The document details Scilex's bid to purchase relevant securities and outlines conditions for potential transactions, including financial obligations and amendments to existing agreements. However, the term sheet is non-binding and subject to approvals from various parties, making it uncertain if the proposed transactions will ultimately be executed.
Read more →ORMPExecution Version Stalking Horse Stock Purchase Term Sheet This term sheet (this " Stalking Horse Term Sheet ") sets forth the principal terms of a proposed equity sale transaction (the " Sale ") between the parties desc
Oramed Pharmaceuticals Inc. has proposed a purchase of equity securities from Sorrento Therapeutics, currently in chapter 11 bankruptcy. The transaction is subject to several conditions, including the approval of the Bankruptcy Court in Texas. The proposed structure involves debtor-in-possession financing, with a total consideration of $105 million, which includes a credit bid and cash payment. The deal's completion hinges on a variety of regulatory approvals and the negotiation of definitive agreements.
Read more →About Oramed Pharmaceuticals Inc.
Headquarters1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next ORMP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime